Lantern Pharma (LTRN) Stock Price, News & Analysis

Company Overview

Lantern Pharma, Inc. is a clinical-stage biopharmaceutical company focused on using artificial intelligence, machine learning and genomic data to discover and develop precision cancer therapies. The company’s approach is designed to identify patient populations most likely to respond to a therapy, with the goal of improving drug-development efficiency and treatment outcomes.

Lantern’s technology platform, known as RADR, analyzes large datasets from clinical studies, scientific literature and other sources to support drug discovery, biomarker identification and clinical-trial design. The company applies this platform to both internally developed drug candidates and potential opportunities involving existing or previously investigated oncology compounds.

Lantern has advanced a pipeline of investigational therapies intended to address cancers with significant unmet medical needs, including certain solid tumors and blood cancers. Its programs are in various stages of preclinical and clinical development, and the company’s operations and clinical activities are primarily centered in the United States.

Founded in 2013 and headquartered in Austin, Texas, Lantern became a publicly traded company in 2020. Panna Sharma serves as the company’s chief executive officer and is a member of its board of directors.

Key Stats

• Today's Range: $0.70 to $0.80
• 50-Day Range: $0.71 to $2.86
• 52-Week Range: $0.70 to $4.58
• Volume: 162,539 shs
• Average Volume: 325,896 shs
• Market Capitalization: $10.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lantern Pharma Stock Analysis - MarketRank™

Lantern Pharma scored higher than 19% of companies evaluated by MarketBeat, and ranked 819th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lantern Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lantern Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantern Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantern Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lantern Pharma has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.15% of the float of Lantern Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lantern Pharma has a short interest ratio ("days to cover") of 1.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lantern Pharma has recently decreased by 12.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantern Pharma does not currently pay a dividend.

Dividend Growth

Lantern Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.93

News Sentiment

Lantern Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Lantern Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lantern Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.50% of the stock of Lantern Pharma is held by insiders.

Percentage Held by Institutions

28.62% of the stock of Lantern Pharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/13/2026
• The ThinkEquity Conference: 10/15/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LTRN
• CIK: 1763950
• Web: www.lanternpharma.com
• Phone: 972-277-1136
• Fax: N/A
• Employees: 16
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -368.02%
• Return on Assets: -148.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.96
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 14,940,000
• Free Float: 13,666,000
• Market Cap: $10.62 million
• Optionable: Optionable
• Beta: 2.33